A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

1078MO MIND-DC: A randomized phase III trial to assess the efficacy of adjuvant dendritic cell vaccination in comparison to placebo in stage IIIB and IIIC melanoma patients

(2020) K. Bol et al.   ANNALS OF ONCOLOGY

Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors

(2018) Mohd Wahid et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

(2018) Margaret K. Callahan et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

(2018) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors

(2018) Garth S. Herbert et al.   VACCINE

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

(2018) Wouter W. van Willigen et al.   Frontiers in Immunology

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

(2017) Paolo A Ascierto et al.   LANCET ONCOLOGY

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2

(2016) Julia M. Greene et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines

(2016) T. J. Vreeland et al.   Expert Review of Clinical Immunology

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma Vaccines

(2014) Junko Ozao-Choy et al.   SURGICAL CLINICS OF NORTH AMERICA

Cellular therapy of cancer with natural killer cells—where do we stand?

(2013) Hans G. Klingemann   CYTOTHERAPY

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

(2010) W. D. Stein et al.   CLINICAL CANCER RESEARCH

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE